Sodium bicarbonate is a chemical compound made of sodium (Na+) and bicarbonate (HCO3-) for which the indications are many.
FDA approved indications include:
Under arrhythmias and cardiovascular instability, sodium bicarbonate can be administered to adults at 4 to 8 hour IV infusions. Each dose should be monitored and planned in a standard protocol to help evaluate the degree of response expected and predicted to understand the necessity to advance further infusions or withhold administration, given its fluid overloading effects.
Metabolic acidosis, related to:
Non-FDA approved indications:
Nebulized sodium bicarbonate is an excellent option to treat chemical injuries resulting from chlorine gas, especially within the pulmonary mucosa. The belief is that when the inhaled gas neutralizes when it reacts with water and bicarbonate within the respiratory system.
After administration, intravenous sodium bicarbonate dissociates to form sodium (Na) and bicarbonate (HCO3). Bicarbonate anions can consume hydrogen ions (H) and subsequently convert to carbonic acid (H2CO3). Carbonic acid subsequently converts to water (H2O) and carbon dioxide (CO2) for excretion from the lungs. The main therapeutic effect of sodium bicarbonate administration is in increasing plasma bicarbonate levels, which are known to buffer excess hydrogen ion concentration, thereby raising solution pH to combat clinical manifestations of acidosis.
Bicarbonate is often a standard element of body fluids and is often regulated by the kidney via secretion or absorption methods to counter regulate changes in serum pH. This action often leads to its second administration as it is known to alkalinize urine that's capable of changing precipitants in urine as well as providing a means of normalizing tubular acid concentration gradients to manage high fluctuations in serum acid-base status changes. This alkalization process enables compounds that would normally precipitate in the renal tubules in acidic conditions to be buffered within the renal tubule, thereby preventing mechanical or chemical damage while also providing increased efficiency within the kidney tubules to excrete acidified substances without disrupting the electrochemical gradient.
NaHCO3 comes in various forms, including oral tablets, IV injections, and IV infusions.
Oral formulations are available via powder, 325 mg, and 650 mg oral tablets.
1 mEq NaHCO3 is 84 mg. 1000 mg = 1 gram of NaHCO3 contains 11.9 mEq of sodium and bicarbonate ions. One 650 mg tablet of NaHCO3 has 7.7 mEq of sodium and bicarbonate ions.
The two primary IV injection formulations of NaHCO3 are as follows:
NaHCO3 IV infusions are made in the following formulations:
Common Uses of Sodium Bicarbonate
Cardiac arrest: Currently, routine bicarbonate administration for cardiac arrest is no longer a recommendation. It should only be administered for cardiac arrest due to hyperkalemia or due to tricyclic antidepressant overdose or in metabolic acidosis.  Dosing is 1 mEq/kg per dose, repeated according to arterial blood gas measurements. Sodium bicarbonate should ideally be given after adequate alveolar ventilation and the initiation of cardiac compressions.
Acute metabolic acidosis: If pH is less than 7.1 or pH less than 7.1 to 7.2 in patients with severe acute kidney injury (oliguria or 2-fold or larger increase in serum creatinine level)
Chronic metabolic acidosis: 50-100 mEq oral tablet can be initiated and titrated according to the ongoing evaluation of acid-base balance.
Lactic acidosis: Use of sodium bicarbonate remains controversial, but is an option if pH is below 7.
Diabetic ketoacidosis: Use of sodium bicarbonate remains controversial in diabetic ketoacidosis since recovery outcome is similar with or without NaHCO3. However, sodium bicarbonate is still a recommendation if the pH is below 7 after 1 hour of fluid administration. Sodium bicarbonate should be given in hypotonic fluid every two hours until pH is at least 7.
Hyperkalemia: When patients with severe hyperkalemia (serum potassium level of more than 6 mEq/L or more than 5.5 mEq/L with arrhythmia or EKG changes) have metabolic acidosis, sodium bicarbonate should be administered. The dose needed is empirical and is unpredictable. Initially, 150 mEq of sodium bicarbonate can be given in 1 liter of 5% dextrose over 4 hours. More can be given if acidosis does not correct with this regimen. If there is a need to decrease serum potassium emergently, 50 mEq of NaHCO3 IV can be given over 5 minutes, followed by other methods of potassium reduction.
Sodium bicarbonate administration can be at varying doses for renal tubular acidosis, and to achieve urine alkalization, it can be given IV for some intoxications like salicylate overdose and to prevent contrast-induced nephropathy.
Sodium bicarbonate can result in a multitude of adverse effects, including:
Administration and extravasation of sodium bicarbonate have known to cause chemical cellulitis due to its basic properties and have resulted in tissue necrosis, ischemia, and tissue death at administration sites.
In large dose administrations, it is known to increase edema and is more commonly noted in those with renal insufficiency given its clearance via the kidneys. This increase in tissue edema appears to be due to excess hyperosmolar state developed during the administration of sodium bicarbonate resulting in fluid retention. This condition can be especially challenging to manage in those with underlying cardiovascular comorbidities, including those with heart failure with intravascular fluid management difficulties.
Due to rapid alkalotic effects, sodium bicarbonate is contraindicated in those with signs/symptoms or laboratory values indicating underlying metabolic or respiratory alkalosis due to the potential for exacerbation of symptoms.
Secondary to deionizing effects on metabolically active ionized serum calcium, sodium bicarbonate is contraindicated in those with hypocalcemia.
Due to its ability to buffer pH and influence acid-base shifts, sodium bicarbonate can also influence a multitude of drug-drug interactions. These include:
These effects are often noted in oral preparations where both medications are taken orally and result in significantly decreased GI absorption due to compound structural alterations due to changes in pH in the GI lumen.
These interactions are due to the effects of sodium bicarbonate on increasing renal tubular pH, thereby increasing passive tubular reabsorption and increasing serum levels of medication.
The administration of sodium bicarbonate can exacerbate hypernatremia.
Rapid or high dose administration of undiluted sodium bicarbonate may lead to decreased CSF pressure and intracranial hemorrhage, particularly in the pediatric population under the age of 2.
Rapid administration of sodium bicarbonate may increase intravascular fluid volume, leading to acute pulmonary edema. Additionally, the medication must be administered judiciously in those with congestive heart failure, significant renal disease, or sodium retention due to exacerbation of sodium retention and edema.
Sodium bicarbonate administration in a rapid infusion or as large boluses can result in acute metabolic alkalosis resulting in reduced serum ionized calcium. This acute shift in ionized calcium can result in tetany. This severe alkalosis is potentially treatable with ammonium chloride. Hypocalcemia may be addressed with calcium gluconate. An addition of 0.9 % NS infusion and potassium supplementation may also be indicated.
Appropriate use of sodium bicarbonate and preventing its potential adverse effects require the involvement of the entire allied team of healthcare professionals. When ordering the administration of sodium bicarbonate, it is imperative that the administering nursing team, pharmacy team, and physician team recognize the indications for the medication, but also observe for any toxicity or side effects from its administration. Despite consistent, systematic checkpoints in evaluating negative outcomes, it is the clinical observation and recognition at the bed-side that consistently improves morbidity and mortality in the setting of patient medication errors, medication-induced reactions, and side effects.
|||Adeva-Andany MM,Fernández-Fernández C,Mouriño-Bayolo D,Castro-Quintela E,Domínguez-Montero A, Sodium bicarbonate therapy in patients with metabolic acidosis. TheScientificWorldJournal. 2014; [PubMed PMID: 25405229]|
|||Lutterman JA,Adriaansen AA,van 't Laar A, Treatment of severe diabetic ketoacidosis. A comparative study of two methods. Diabetologia. 1979 Jul; [PubMed PMID: 38163]|
|||Arieff AI, Indications for use of bicarbonate in patients with metabolic acidosis. British journal of anaesthesia. 1991 Aug; [PubMed PMID: 1653584]|
|||Mirrakhimov AE,Ayach T,Barbaryan A,Talari G,Chadha R,Gray A, The Role of Sodium Bicarbonate in the Management of Some Toxic Ingestions. International journal of nephrology. 2017; [PubMed PMID: 28932601]|
|||Erejuwa OO,Aja DOJ,Uwaezuoke NI,Nwadike KI,Ezeokpo BC,Akpan JL,Nwobodo NN,Araromi E,Asika E, Effects of honey supplementation on renal dysfunction and metabolic acidosis in rats with high-fat diet-induced chronic kidney disease. Journal of basic and clinical physiology and pharmacology. 2020 May 12; [PubMed PMID: 32396139]|
|||Cevik Y,Onay M,Akmaz I,Sezigen S, Mass casualties from acute inhalation of chlorine gas. Southern medical journal. 2009 Dec [PubMed PMID: 20016425]|
|||Pentel P,Benowitz N, Efficacy and mechanism of action of sodium bicarbonate in the treatment of desipramine toxicity in rats. The Journal of pharmacology and experimental therapeutics. 1984 Jul; [PubMed PMID: 6086872]|
|||Spivey WH,Lathers CM,Malone DR,Unger HD,Bhat S,McNamara RN,Schoffstall J,Tumer N, Comparison of intraosseous, central, and peripheral routes of sodium bicarbonate administration during CPR in pigs. Annals of emergency medicine. 1985 Dec; [PubMed PMID: 2998236]|
|||Velissaris D,Karamouzos V,Pierrakos C,Koniari I,Apostolopoulou C,Karanikolas M, Use of Sodium Bicarbonate in Cardiac Arrest: Current Guidelines and Literature Review. Journal of clinical medicine research. 2016 Apr [PubMed PMID: 26985247]|
|||Boyd JH,Walley KR, Is there a role for sodium bicarbonate in treating lactic acidosis from shock? Current opinion in critical care. 2008 Aug; [PubMed PMID: 18614899]|
|||Chiasson JL,Aris-Jilwan N,Bélanger R,Bertrand S,Beauregard H,Ekoé JM,Fournier H,Havrankova J, Diagnosis and treatment of diabetic ketoacidosis and the hyperglycemic hyperosmolar state. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2003 Apr 1 [PubMed PMID: 12668546]|
|||Abuelo JG, Treatment of Severe Hyperkalemia: Confronting 4 Fallacies. Kidney international reports. 2018 Jan [PubMed PMID: 29340313]|
|||El-Solh AA,Abou Jaoude P,Porhomayon J, Bicarbonate therapy in the treatment of septic shock: a second look. Internal and emergency medicine. 2010 Aug; [PubMed PMID: 20169423]|
|||Łoniewski I,Wesson DE, Bicarbonate therapy for prevention of chronic kidney disease progression. Kidney international. 2014 Mar; [PubMed PMID: 24107852]|
|||Geng X,Yu J,Xu J,Jin S,Shao W,Wang Y,Guo M,Cao X,Zou J,Xu X,Ding X, Role of magnesium in the risk of intradialytic hypotension among maintenance hemodialysis patients. Hemodialysis international. International Symposium on Home Hemodialysis. 2020 May 12; [PubMed PMID: 32395903]|
|||Koski C,Sarkar N,Bose S, Cytotoxic and osteogenic effects of crocin and bicarbonate from calcium phosphates for potential chemopreventative and anti-inflammatory applications in vitro and in vivo. Journal of materials chemistry. B. 2020 Mar 11; [PubMed PMID: 32064472]|